![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessPharmacological targeting of eIF4E in primary CLL lymphocytes
-
Chapter
DNA-PK in CLL Chemotherapy
DNA is the principal target of many conventional anticancer agents, and inhibition of DNA repair is one of the most promising strategies in novel cancer therapy. Many studies demonstrated that nonhomologous en...
-
Article
Open AccessKi 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemoth...
-
Article
ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro
-
Article
Reply to ‘Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4’ by Chow et al
-
Article
Imatinib sensitizes CLL lymphocytes to chlorambucil
The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respe...